Compare ZDGE & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZDGE | COCH |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | 55 | 47 |
| Industry | Computer Software: Prepackaged Software | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 47.1M |
| IPO Year | 2016 | N/A |
| Metric | ZDGE | COCH |
|---|---|---|
| Price | $3.21 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 66.2K | ★ 123.0K |
| Earning Date | 06-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,398,000.00 | N/A |
| Revenue This Year | $3.27 | $1.58 |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $0.36 |
| 52 Week High | $4.70 | $1.91 |
| Indicator | ZDGE | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 46.96 |
| Support Level | $2.90 | $0.63 |
| Resistance Level | $3.19 | $0.73 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 36.00 | 42.95 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.